Hexpol TPE has announced a 57 Million SEK investment at their company in Åmål, Sweden, to support increasing demand and evolving market requirements. The investment will expand production capacity and ensure product safety standards across their materials portfolio. A new production hall is being constructed, dedicated to medical production, with strict cleanliness, traceability, and reproducibility controls. It has been designed to minimise contamination risks and will house a new twin-screw compounding line with gravimetric feeders and advanced monitoring systems adopted for medical production. Construction of the new production hall began in September 2021. The aim is to complete the project by autumn 2022.
The company specialises in TPE materials for sensitive and regulated applications such as medical devices, toys, consumer, automotive and food contact. Sustainability and biobased materials are also driving their strategy. Hexpol TPE produced their first medical compounds in the 1990s and launched the Mediprene range in 2004. Continuous investment in technology, people and processes contributed to the company becoming the first TPE compounder in Europe to gain the ISO 13485 accreditation in 2007.